Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The formatting was awful. You would also think in this day and age, our government would be able to upload a searchable pdf rather than a pdf of a xerox...
I don't think anybody thought a CRL was possible, which is why my thesis was that AMRN was fairly priced in the mid $20s.
I think most brokers observe the 4 pm expiration time. I know Robinhood will start exercising options as early as 3 pm or will sell the contracts if you don't have the funds.
Lipidologists were the ideal experts to weigh in on label expansion because patients in Vascepa's target population have a lipid disorder resulting in heart disease, or as you put it, "abnormally high blood lipids (fats) cause a disease state." Contrary to your beliefs, however, lipidologists are also aware of the many diseases that cause lipid disorders. These causes can be categorized as primary and secondary causes. Primary causes include genetic defects in triglyceride synthesis and metabolism (yes, it's really, "I gOT bAd GeNEs"). Secondary causes, like diabetes and inflammation, are also known to alter lipid metabolism resulting in lipid disorders.
Here are some great review papers by the National Lipid Association's official publication, Journal of Clinical Lipidology. While these reviews are geared towards young patients, they provide a thorough discussion on primary and secondary causes of hypertriglyceridemia,
True true, but all the same, I am not going to be greedy. Today's after-hours action looks like $27-28 is a pretty strong ceiling. If we rise premarket, I will probably sell half at any price above $27 and let the rest ride with a stop for the remaining half at $26. If we pull-back to $23-25, I might buy back in if nothing more attractive pops on my radar.
That sucks. If it's any consolation, my bank begrudgingly approved the trade but I am on their risk assessment team's radar, which is never a good thing... :/
Right, but that doesn't mean you can't long AMRN on margin, you just need to maintain a margin maintenance requirement of 100%. To be fair, that's really high and usually reserved for penny stocks or really iffy securities.
My response to your post was that doctors clearly have no problem with waiting. After all, they waited for REDUCE-IT results and they waited for sNDA approval. The fact that prescriptions are increasing and are expected to continue increasing after label expansion is evidence of this. Amarin knows this as well because they are increasing their sales team as well as planning DTC advertising. Does that make sense?
For sure! Alzheimer's is a devastating disease and not just for the patient. Throwing everything at it to see what sticks, however, is not the right approach and is probably why many treatments end in disappointment. We are only now beginning to realize just how complex the disease is and how it intertwines with other diseases.
Except everybody who could benefit from a primary prevention standpoint does not have prescription. We know this because prescription numbers are increasing and are anticipated to increase after label expansion. This would not be the case if the market was saturated by off label use.
As for coverage, maybe you have good insurance, but I know at least Humana has Vascepa as a Tier 4. And I'm sure other board members can speak about their challenges with getting a prescription.
For sure! There is a lot of overlap in comorbidities within these populations. And so, it's very possible that patients who may benefit from Alzheimer's prevention may already have a prescription.
It's being ignored because the trials are still at an early stage and so generics will probably be around by the time anything meaningful comes from it.
There is no confidential data. Target companies will literally hand over everything to a team of analysts from the other company for examination. Any attempt to hide documentation or material during this process will jeopardize the negotiation and may result in penalties when it is ultimately discovered.